BEAUTY HEALTH CO/THE (SKIN) Fundamental Analysis & Valuation

NASDAQ:SKIN • US88331L1089

Current stock price

0.9052 USD
-0.02 (-2.4%)
At close:
0.9052 USD
0 (0%)
After Hours:

This SKIN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. SKIN Profitability Analysis

1.1 Basic Checks

  • In the past year SKIN has reported negative net income.
  • SKIN had a positive operating cash flow in the past year.
  • In the past 5 years SKIN reported 4 times negative net income.
  • The reported operating cash flow has been mixed in the past 5 years: SKIN reported negative operating cash flow in multiple years.
SKIN Yearly Net Income VS EBIT VS OCF VS FCFSKIN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M -300M

1.2 Ratios

  • With a Return On Assets value of -1.90%, SKIN perfoms like the industry average, outperforming 48.65% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -15.59%, SKIN is in line with its industry, outperforming 43.24% of the companies in the same industry.
Industry RankSector Rank
ROA -1.9%
ROE -15.59%
ROIC N/A
ROA(3y)-5.64%
ROA(5y)-8.65%
ROE(3y)-80.11%
ROE(5y)-67.57%
ROIC(3y)N/A
ROIC(5y)N/A
SKIN Yearly ROA, ROE, ROICSKIN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

1.3 Margins

  • Looking at the Gross Margin, with a value of 67.68%, SKIN is in line with its industry, outperforming 54.05% of the companies in the same industry.
  • In the last couple of years the Gross Margin of SKIN has grown nicely.
  • The Profit Margin and Operating Margin are not available for SKIN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.68%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.36%
GM growth 5Y3.7%
SKIN Yearly Profit, Operating, Gross MarginsSKIN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. SKIN Health Analysis

2.1 Basic Checks

  • SKIN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, SKIN has more shares outstanding
  • SKIN has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for SKIN has been reduced compared to a year ago.
SKIN Yearly Shares OutstandingSKIN Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 50M 100M 150M
SKIN Yearly Total Debt VS Total AssetsSKIN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • Based on the Altman-Z score of -0.48, we must say that SKIN is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of SKIN (-0.48) is worse than 70.27% of its industry peers.
  • The Debt to FCF ratio of SKIN is 11.27, which is on the high side as it means it would take SKIN, 11.27 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 11.27, SKIN is in line with its industry, outperforming 45.95% of the companies in the same industry.
  • A Debt/Equity ratio of 3.94 is on the high side and indicates that SKIN has dependencies on debt financing.
  • With a Debt to Equity ratio value of 3.94, SKIN is not doing good in the industry: 75.68% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 3.94
Debt/FCF 11.27
Altman-Z -0.48
ROIC/WACCN/A
WACC6.37%
SKIN Yearly LT Debt VS Equity VS FCFSKIN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 1.66 indicates that SKIN should not have too much problems paying its short term obligations.
  • SKIN has a Current ratio (1.66) which is comparable to the rest of the industry.
  • A Quick Ratio of 1.40 indicates that SKIN should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.40, SKIN is in line with its industry, outperforming 56.76% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.66
Quick Ratio 1.4
SKIN Yearly Current Assets VS Current LiabilitesSKIN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. SKIN Growth Analysis

3.1 Past

  • The earnings per share for SKIN have decreased strongly by -11.73% in the last year.
  • Looking at the last year, SKIN shows a very negative growth in Revenue. The Revenue has decreased by -10.02% in the last year.
  • Measured over the past years, SKIN shows a very strong growth in Revenue. The Revenue has been growing by 20.36% on average per year.
EPS 1Y (TTM)-11.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)-10.02%
Revenue growth 3Y-6.32%
Revenue growth 5Y20.36%
Sales Q2Q%-1.32%

3.2 Future

  • SKIN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 45.35% yearly.
  • SKIN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.77% yearly.
EPS Next Y45.18%
EPS Next 2Y3.4%
EPS Next 3Y45.35%
EPS Next 5YN/A
Revenue Next Year0.38%
Revenue Next 2Y2.47%
Revenue Next 3Y2.77%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
SKIN Yearly Revenue VS EstimatesSKIN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2032 100M 200M 300M 400M 500M
SKIN Yearly EPS VS EstimatesSKIN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 0 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

3

4. SKIN Valuation Analysis

4.1 Price/Earnings Ratio

  • SKIN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year SKIN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SKIN Price Earnings VS Forward Price EarningsSKIN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

  • The rest of the industry has a similar Enterprise Value to EBITDA ratio as SKIN.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of SKIN indicates a rather cheap valuation: SKIN is cheaper than 97.30% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 3.58
EV/EBITDA 34.2
SKIN Per share dataSKIN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SKIN's earnings are expected to grow with 45.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.4%
EPS Next 3Y45.35%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SKIN Dividend Analysis

5.1 Amount

  • SKIN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SKIN Fundamentals: All Metrics, Ratios and Statistics

BEAUTY HEALTH CO/THE

NASDAQ:SKIN (4/2/2026, 8:00:02 PM)

After market: 0.9052 0 (0%)

0.9052

-0.02 (-2.4%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)03-12
Earnings (Next)05-06
Inst Owners89.58%
Inst Owner Change0%
Ins Owners11.44%
Ins Owner Change26.67%
Market Cap115.66M
Revenue(TTM)300.79M
Net Income(TTM)-9.52M
Analysts51.43
Price Target1.73 (91.12%)
Short Float %13.63%
Short Ratio21.75
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-22.28%
Min EPS beat(2)-30.18%
Max EPS beat(2)-14.38%
EPS beat(4)2
Avg EPS beat(4)37.24%
Min EPS beat(4)-30.18%
Max EPS beat(4)155.64%
EPS beat(8)6
Avg EPS beat(8)48.95%
EPS beat(12)9
Avg EPS beat(12)45.22%
EPS beat(16)13
Avg EPS beat(16)450.46%
Revenue beat(2)2
Avg Revenue beat(2)2.41%
Min Revenue beat(2)0.99%
Max Revenue beat(2)3.83%
Revenue beat(4)4
Avg Revenue beat(4)3.67%
Min Revenue beat(4)0.99%
Max Revenue beat(4)6.94%
Revenue beat(8)6
Avg Revenue beat(8)1.78%
Revenue beat(12)7
Avg Revenue beat(12)-0.2%
Revenue beat(16)11
Avg Revenue beat(16)2.38%
PT rev (1m)-13.61%
PT rev (3m)-12.5%
EPS NQ rev (1m)-35.48%
EPS NQ rev (3m)-118.75%
EPS NY rev (1m)0%
EPS NY rev (3m)-24.03%
Revenue NQ rev (1m)-4.73%
Revenue NQ rev (3m)-5.14%
Revenue NY rev (1m)-3.85%
Revenue NY rev (3m)-3.72%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.38
P/FCF 3.58
P/OCF 3.09
P/B 1.89
P/tB N/A
EV/EBITDA 34.2
EPS(TTM)-0.2
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)0.25
FCFY27.95%
OCF(TTM)0.29
OCFY32.41%
SpS2.35
BVpS0.48
TBVpS-0.79
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1.9%
ROE -15.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.68%
FCFM 10.75%
ROA(3y)-5.64%
ROA(5y)-8.65%
ROE(3y)-80.11%
ROE(5y)-67.57%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.36%
GM growth 5Y3.7%
F-Score6
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 3.94
Debt/FCF 11.27
Debt/EBITDA 33.24
Cap/Depr 24.78%
Cap/Sales 1.72%
Interest Coverage N/A
Cash Conversion 518.25%
Profit Quality N/A
Current Ratio 1.66
Quick Ratio 1.4
Altman-Z -0.48
F-Score6
WACC6.37%
ROIC/WACCN/A
Cap/Depr(3y)29.43%
Cap/Depr(5y)45.52%
Cap/Sales(3y)2.34%
Cap/Sales(5y)3.56%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-11.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y45.18%
EPS Next 2Y3.4%
EPS Next 3Y45.35%
EPS Next 5YN/A
Revenue 1Y (TTM)-10.02%
Revenue growth 3Y-6.32%
Revenue growth 5Y20.36%
Sales Q2Q%-1.32%
Revenue Next Year0.38%
Revenue Next 2Y2.47%
Revenue Next 3Y2.77%
Revenue Next 5YN/A
EBIT growth 1Y72.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year254.97%
EBIT Next 3Y83.17%
EBIT Next 5YN/A
FCF growth 1Y246.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y132.34%
OCF growth 3YN/A
OCF growth 5YN/A

BEAUTY HEALTH CO/THE / SKIN Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BEAUTY HEALTH CO/THE?

ChartMill assigns a fundamental rating of 2 / 10 to SKIN.


What is the valuation status of BEAUTY HEALTH CO/THE (SKIN) stock?

ChartMill assigns a valuation rating of 3 / 10 to BEAUTY HEALTH CO/THE (SKIN). This can be considered as Overvalued.


What is the profitability of SKIN stock?

BEAUTY HEALTH CO/THE (SKIN) has a profitability rating of 2 / 10.


What is the earnings growth outlook for BEAUTY HEALTH CO/THE?

The Earnings per Share (EPS) of BEAUTY HEALTH CO/THE (SKIN) is expected to grow by 45.18% in the next year.